Cohort study
Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer
- Retrospective cohort study
Authors' conclusion
In a large genomic tumor-profiling registry of patients with solid cancers, alterations in KRAS and STK11 were associated with an increased risk for ATE independent of cancer type.
Study context
- Population
- Adults with solid cancers who underwent MSK-IMPACT tumour profiling, 2014–2016160 arterial thromboembolism (ATE) events
- Participants
- 11,871 adults
- Exposure
- Tumour genomic alterations vs no alteration
- Outcome
- ATE (MI, coronary revascularization, ischemic stroke, peripheral arterial occlusion or limb revascularization)
- Follow-up
- Up to 1 year
Main finding
As reported in the abstract
ATE, independent of tumor type
Hazard ratio (95% CI)P value
KRAS
1.98(1.34–2.94)
P = 0.015STK11
2.51(1.44–4.38)
P = 0.015Observational data: associations, not effects.
Original publication
Tumor Genomic Profile Is Associated With Arterial Thromboembolism Risk in Patients With Solid Cancer. JACC CardioOncol. Published 18 April 2023. doi:10.1016/j.jaccao.2023.01.009
Summarised from the published abstract; every number is checked against it